Panmure Gordon Reiterates Hold Rating for Immunodiagnostic Systems Hldgs PLC (IDH)
Immunodiagnostic Systems Hldgs PLC (LON:IDH)‘s stock had its “hold” rating restated by investment analysts at Panmure Gordon in a note issued to investors on Monday. They currently have a GBX 600 ($10.10) price target on the stock. Panmure Gordon’s target price points to a potential upside of 13.64% from the stock’s previous close.
Immunodiagnostic Systems Hldgs PLC (LON:IDH) opened at 489.00 on Monday. Immunodiagnostic Systems Hldgs PLC has a 52-week low of GBX 405.00 and a 52-week high of GBX 593.00. The stock has a 50-day moving average of GBX 528.2 and a 200-day moving average of GBX 529.1.
The company also recently announced a dividend, which is scheduled for Friday, August 22nd. Investors of record on Wednesday, July 23rd will be paid a dividend of GBX 8.50 ($0.14) per share. This represents a dividend yield of 1.57%. The ex-dividend date is Wednesday, July 23rd.
A number of other firms have also recently commented on IDH. Analysts at N+1 Singer downgraded shares of Immunodiagnostic Systems Hldgs PLC to a “sell” rating in a research note on Monday. They now have a GBX 480 ($8.08) price target on the stock, down previously from GBX 525 ($8.83). Separately, analysts at FinnCap reiterated a “hold” rating on shares of Immunodiagnostic Systems Hldgs PLC in a research note on Monday. They now have a GBX 500 ($8.41) price target on the stock. Finally, analysts at FinnCap raised their price target on shares of Immunodiagnostic Systems Hldgs PLC from GBX 450 ($7.57) to GBX 500 ($8.41) in a research note on Wednesday, July 23rd. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating and five have issued a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of GBX 511.67 ($8.61).
Immunodiagnostic Systems Holdings plc (LON:IDH) is engaged in manufacturing and distributing medical diagnostic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.